Biotech

All Articles

Despite blended market, an equity capital resurgence could be being available in Europe: PitchBook

.While the biotech investment performance in Europe has actually decreased relatively following a CO...

8 months after a $213M fundraise, genetics publisher Volume creates reduces

.After raising $213 million in 2023-- one of the year's biggest exclusive biotech shots-- Tome Biosc...

BioMarin builds director group with biotech veterinarians-- Chutes &amp Ladders

.Invite to today's Chutes &amp Ladders, our summary of significant leadership hirings, firings and r...

Biopharma Q2 VC hit highest degree considering that '22, while M&ampA slowed

.Venture capital financing into biopharma rose to $9.2 billion around 215 deals in the second quarte...

Bicara, Zenas look for IPOs to push late-phase resources toward market

.Bicara Therapeutics and Zenas Biopharma have delivered new motivation to the IPO market with filing...

Genentech to close cancer immunology study department

.Genentech is going to shut its own cancer cells immunology research study department, and system mi...

Kezar falls strong growth but to show its worth in period 1 test

.Kezar Life Sciences is actually falling its unpromising stage 1 strong lump medicine as the biotech...

Acelyrin goes down izokibep, lays off 3rd of team

.Regardless of izokibep sustaining its own newly found winning touch in the medical clinic, Acelyrin...

Rivus' stage 2 obesity-related heart failure test hits endpoint

.Rivus Pharmaceuticals has plumped up the customers of its own fat-busting, muscle-sparing medicine ...

Ovid stops preclinical work, IV program after soticlestat fall short

.Ovid Rehab presently revealed last month that it was trimming its own headcount as the business nav...